Skip to content

Evaluating the Effectiveness of Hemoperfusion Combined with Continuous Renal Replacement Therapy for Septic Shock with Acute Kidney Injury: a Multicenter, Open-Labelled, Randomized, Parallel Controlled Study

Evaluating the Effectiveness of Hemoperfusion Combined with Continuous Renal Replacement Therapy for Septic Shock with Acute Kidney Injury: a Multicenter, Open-Labelled, Randomized, Parallel Controlled Study

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000036992
Enrollment
Unknown
Registered
2020-08-26
Start date
2020-10-01
Completion date
Unknown
Last updated
2020-09-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

sepsis acute kidney disease

Interventions

control group:CRRT
experimental group:CRRT+HP

Sponsors

Shanghai Sixth Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1) Aged >= 18 years; 2) In line with the definition of sepsis in the 2016 campaign to save sepsis (SSCM). Sepsis was defined as infection (microbial culture basis) + organ dysfunction (sofa) >= 2 points; 3) The AKI diagnostic criteria of 2012 KDIGO guidelines were met; 4) Has received standard treatment including fluid resuscitation, vasoactive drugs, antibiotics, respiratory support, nutritional support, vital signs monitoring, etc. (according to the 2016 SSCM guidelines); 5) Patients and their family members were informed and voluntarily participated in the study and signed informed consent.

Exclusion criteria

Exclusion criteria: 1) The written consent of the patient or client cannot be obtained; 2) Patients who were pregnant or suspected of pregnancy or lactation at the time of inclusion; 3) Organ transplant recipients within one year; 4) Those who have been in ICU in recent 28 days; 5) Patients with extensive metastasis of malignant tumor; 6) End stage renal disease requiring maintenance dialysis; 7) Patients with acute myocardial infarction in the past 4 weeks; 8) Patients with uncontrollable bleeding (acute hemorrhage > 3upc in the past 24 hours); 9) Patients with severe leukopenia (< 0.5 x 10^9 / L) or severe thrombocytopenia (< 30 x 10^9 / L); 10) Patients allergic to hemoperfusion and filter; 11) Anticoagulant allergy; 12) In any other case, the researcher thinks that it is not suitable to participate in this study, such as: the terminal state of chronic disease, and there is no possibility of survival or discharge.

Design outcomes

Primary

MeasureTime frame
28 day mortality;

Countries

China

Contacts

Public ContactNiansong Wang

Shanghai Sixth Hospital

wangniansong2012@163.com+86 18930177399

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026